Buradasınız

Anasayfa » Content

Prolaktinoma: Olgu Sunumu ve Hiperprolaktinemiye Güncel Yaklaşım

PROLACTINOMA: A CASE REPORT AND CURRENT APPROACH TO HYPERPROLACTINEMIA

Journal Name:

  • Türkiye Aile Hekimliği Dergisi

Publication Year:

  • 2005

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Prolactin is a hormon secreted from anterior hypophysis. Its main functions are lactation, reproduction, growth and osmoregula-tion. Hyperprolactinemia is the most common endocrine disorder of the hypothalamic-pituitary axis. Hyperprolactinemia often causes hypogonadism and galactorrhea in both sexes, while men¬strual dysfunction and infertility in females and empotance in males are the most common symptoms. In addition, there may be neurological symptoms by mass effect in the sellar area if its caused by a macroprolactinoma. Dopamine agonists (bromocriptine, pergolide, cabergoline) are the first step choices in the treatment. Main indications of surgery in prolactinomas are intoler¬ance of the medication, and tumors not responding to dopamine agonists. Occasionally, these may ultimately require radiation therapy. In this article we review guidelines which can help the diagnosis and treatment of hyperprolactinemia.
Bookmark/Search this post with
Abstract (Original Language): 
Prolaktin, önhipofizden salınan, esas fonksiyonları laktasyon, üreme, büyüme ve osmoregülasyon olan bir hormondur. Hipotalamus-hipofiz aksının en sık rastlanan endokrin bozukluğu hiperprolaktinemidir. Kadınlarda adet düzensizliği ve infertilite, erkeklerde empotans en sık görülen semptomlar iken, hiperpro-laktinemi her iki cinste çoğu kez hipogonadizm ve galaktoreye neden olur. Etken makroprolaktinoma ise sella bölgesinde basıya bağlı nörolojik belirtiler görülebilir. Tedavide ilk seçenek dopamin agonistleri; bromokriptin, pergolid ve kabergolindir. ilaç tedavi¬sine tahammülsüzlük ya da cevapsızlık söz konusu ise cerrahi girişim ve sıklıkla da radyasyon tedavisi gerekir. Bu yazı, hiperpro-laktinemi tanı ve tedavisine yardımcı olabilecek bir kılavuz ver¬mektedir.
FULL TEXT (PDF): 
PDF icon arastrmx_116859_9_pp_85-89.pdf
  • 2
85-89
  • Turkish

REFERENCES

References: 

1. Biller BM, Luciano A, Crosignani PG, Molitch M, Olive D, Rebar R, Sanfilippo J, Webster J, Zacur H. Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med 1999; 44(12 Suppl): 1075-84.
2. Nomikos P, Buchfelder M, Fahlbusch R. Current management of prolactinomas. J Neurooncol 2001; 54: 139-50.
3.
Molvalıla
r S. Ön ve arka hipofiz hastalıkları. Temel İç Hastalıkları'nda. Ed. İliçin G, Ünal S, Biberoğlu K, Akalın S, Süleymanlar. 2. cilt. Ankara, Güneş Kitabevi, 1996; 1688-98.
4.
Sonin
o N, Navarrini C, Ruini C, Fallo F, Boscaro M, Fava GA. Life events in the pathogenesis of hyperprolactinemia. Eur J Endocrinol 2004;
151: 61-5.
5. Rosato F, Garofalo P. Hyperprolactinemia: from diagnosis to treatment. Minerva Pediatr 2002; 54: 547-52.
6. Biler BM. Hyperprolactinemia. Int J Fertil Womens Med 1999; 44: 74-7.
7. Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med 2002; 20: 365-74.
8. Hershlag A, Matthew C, Çeviri: Günaydın G, Taner MZ. Endokrin Hastalıklar. Novak Jinekoloji'de. Ed. Berek JS, çeviri ed. Erk A. 13. baskı. İstanbul, Nobel, 2004; 871-930.
9. Chiodini I, Liuzzi A. PRL-secreting pitiutary adenomas in pregnancy. J Endocrinol Invest 2003;26: 96-9.
10. Molitch ME. Management of prolactinomas during pregnancy. J Reprod
Med 1999; 44(12 Suppl): 1121-6.
11. Molitch ME. Pituitary diseases in pregnancy. Semin Perinatol 1998; 22: 457¬70.
12. Badawy SZ, Marziale JC, Rosenbaum AE, Chang JK, Joy SE. The long-term effects of pregnancy and bromocriptine treatment on prolactinomas-the value of radiologic studies. Early Pregnancy 1997; 3: 306-11.
13. Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G. Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs
2002; 11: 787-800.
14. Colao A, Di Sarno A, Cappabianca P, Di Soma C, Pivonello R, Lombardini G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003 20; 349: 2023-33.
88 |
Toprak D | Prolaktinoma-Olgu Sunumu ve Hiperprolaktinemiye Güncel Yaklaşım
15. Davis JR. Prolactin and reproductive medicine. Curr Opin Obstet Gynecol
2004;16: 331-7.
16. Molitch ME. Dopamine resistance of prolactinomas. Pituitary 2003; 6: 19-27.
17. Webster J. Clinical management of prolactinomas. Baillieres Best Pract Res.
Clin Endocrinol Metab 1999; 13: 395-408.
18. Passos VQ, Souza JJ, Musolino NR, Bronstein MD. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin
Endocrinol Metab 2002; 87: 3578-82.
19. Molitch ME. Disorders of prolactin secretion. Endocrinol Metab Clin North Am 2001; 30: 585-610.

Thank you for copying data from http://www.arastirmax.com